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Abstract: Natural products are a prolific source for the identification of new biologically active
compounds. In the present work, we studied the in vitro and in vivo antimalarial efficacy and
ADME-Tox profile of a molecular hybrid (AM1) between 4-aminoquinoline and a quinolizidine
moiety derived from lupinine (Lupinus luteus). The aim was to find a compound endowed with the
target product profile-1 (TCP-1: molecules that clear asexual blood-stage parasitaemia), proposed
by the Medicine for Malaria Venture to accomplish the goal of malaria elimination/eradication.
AM1 displayed a very attractive profile in terms of both in vitro and in vivo activity. By using
standard in vitro antimalarial assays, AM1 showed low nanomolar inhibitory activity against
chloroquine-sensitive and resistant P. falciparum strains (range IC50 16–53 nM), matched with a
high potency against P. vivax field isolates (Mean IC50 29 nM). Low toxicity and additivity with
artemisinin derivatives were also demonstrated in vitro. High in vivo oral efficacy was observed
in both P. berghei and P. yoelii mouse models with IC50 values comparable or better than those of
chloroquine. The metabolic stability in different species and the pharmacokinetic profile in the mouse
model makes AM1 a compound worth further investigation as a potential novel schizonticidal agent.
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1. Introduction
Malaria is an infectious disease caused by Plasmodium parasites; two species, P. falciparum and
P. vivax, are responsible for more than 400,000 deaths/year worldwide. The majority of fatalities (90%),
mostly children below the age of five and pregnant women, occur in Africa, and in particular in the
sub-Saharan regions [1].
Increased funding and efforts to find new, effective treatments, together with improvements in
the use of control tools (insecticide-treated nets and residual indoor spraying), succeeded in reducing
malaria incidence by 41% between 2000 and 2015. Similarly, global malaria mortality decreased by
62% over the same years. However, the emergence of parasite resistance to the current combination
therapies based on artemisinin derivatives (ACTs) may frustrate all these efforts [2–5]. Moreover,
in some of the countries where P. falciparum has been eliminated (Central Asia, Argentina, Belize,
Mexico, and large parts of China) there is growing evidence for an increase in morbidity and mortality
due to P. vivax infection [6–8]. For these reasons, the discovery and development of new drugs active
against different Plasmodium species remains a high priority.
The 4-aminoquinoline class of drugs, represented by the classical antimalarial agent chloroquine
(CQ), has been highly successful in the treatment of malaria for decades before resistance emerged and
spread. Another member of the family, amodiaquine (AQ), is still used in ACT [9]. For their stability,
bioavailability, and efficacy, quinoline-type drugs are extremely effective as blood-stage schizonticidal
agents. However, their usage is hampered by the large diffusion of resistance of P. falciparum and P. vivax
strains to CQ, and cross-resistance to AQ and mefloquine. In countries where CQ use was discontinued,
studies have shown that, in the absence of drug pressure, CQ-resistant strains of P. falciparum have been
replaced by CQ-sensitive isolates [10]. Therefore, the development of CQ analogues as multi-species
antimalarial agents may still be valid and has been recently highlighted and reviewed [11,12].
Chemical modification of the side chain of 4-aminoquinolines, either in length or with the
introduction of bulky basic groups, has been shown to overcome CQ resistance. Over the years,
several compounds active also in CQ-resistant strains have been synthesized and some of them,
including one from our group, reached pre-clinical testing [13–15]. Ferroquine and AQ 13, for example,
are in advanced clinical phase II evaluation [16–20].
In order to eliminate malaria, the antimalarial target product profiles have been recently revised
by the Medicine for Malaria Venture (MMV), highlighting the importance of developing compounds
that will be able to target different parasite species and stages, maintaining a good ADME/PK profile
which can be relevant for combination therapies [21].
A few years ago, we synthesized and studied a new series of 7-chloro-4-aminoquinolines
characterized by the presence of a bulky quinolizidinyl or quinolizidinylalkyl side chain, the latter
derived from the natural product (−)-lupinine, an alkaloid extracted from Lupinus luteus seeds [22].
Among them, 7-chloro-4-(N-lupinyl)aminoquinoline, named (−)-AM1, was selected for further
physicochemical and biological characterization. The results indicated that the antiplasmodial activity
of (−)-AM1 was likely due to inhibition of hemozoin formation. This was directly tested in a
beta-hematin inhibitory assay in vitro, and it was substantiated by measuring the lipophilicity of
(−)-AM1 [23]. In fact, (−)-AM1 is more lipophilic than chloroquine and thus able to accumulate
at the interface between lipids and water where hemozoin formation is reported to occur [24].
The efficacy against CQ-resistant strains of P. falciparum could be ascribed to the ability of (−)-AM1
to block drug efflux by hydrophobic interactions with Pf CRT, the transporter responsible for
CQ resistance [23]. Due to the limited market supply of (−)-lupinine, the total synthesis of
7-chloro-4-(N-lupinyl)aminoquinoline, the most active compound of the series, was developed
resulting in a racemic product called (±)-AM1 (Figure 1) [25].
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Both the racemate and its purified enantiomers showed potent antimalarial in vitro activity 
against both CQ-S (D10) and CQ-R (W-2) strains of P. falciparum, and a good therapeutic index [25]. 
In the present work, we extended the previous observations by completing in vivo efficacy 
studies of racemic AM1 and its purified enantiomers in two rodent malaria models (P. berghei and  
P. yoelii) with different susceptibilities to CQ, and activity studies against P. vivax clinical isolates. 
We also evaluated the ADME-Tox profiles in vivo and in vitro. 
2. Results 
2.1. In Vitro Antimalarial Activity against P. falciparum and P. vivax 
Racemic AM1 and its purified enantiomers (Figure 1) showed an antimalarial activity in vitro in 
the low nanomolar range (IC50 = 16–53 nM) when tested against both CQ-S (D10) and CQ-R strains of 
P. falciparum (FCR1 and FCR3), including a multidrug-resistant parasite TM91C235 (isolated in 
Thailand) (Table 1). All the compounds had very low toxicity and an excellent selectivity index  
(SI > 1000) against human endothelial cells and fibroblasts, and mouse cell lines, as previously 
reported [25]. Furthermore, (±)-AM1 showed remarkable antimalarial activity against 10 different field 
isolates of P. vivax with potency about 3 times higher than that of CQ (Table 1, right column). 
Table 1. In vitro antimalarial activities of the AM1 racemate and its enantiomers on P. falciparum 
laboratory strains and P. vivax field isolates. 
Compounds 
P. falciparum IC50 (nM) a P. vivax IC50 (nM) b 
D10 c (CQ-S) W-2 c (CQ-R) TM91C253 FCR1 FCR3 Field Isolates
(±)-AM1 16.15 35.44 - - - 29.72 
(−)-AM1 23.98 53.67 16.74 32.87 23.28 - 
(+)-AM1 17.49 35.77 - - - - 
CQ 23.72 437.62 199.46 181.93 112.56 86.66 
a The assay was evaluated after 72 h incubation, using the parasite lactate dehydrogenase (pLDH) 
method, mean of 3 different experiments. b IC50 results from 10 field isolates from the Thai–Burmese 
Border. c Data already published in [25]. 
When tested in combination studies with dihydroartemisinin (DHA) using D10 (CQ-S) and W-2 
(CQ-R) parasites, the isobolograms showed that (−)-AM1 had additive activity with DHA (FIC < 2), 
with a non-significant trend toward antagonism (Figure 2A,B). The results are similar to those 
obtained with CQ (Figure 2C,D). 
Figure 1. Structure of investigated compounds: 7-chloro-N-(((1S,9aR)-octahydro-1H-quinolizin-1-yl)
ethyl)quinolin-4-a ine (−)-A 1; 7-chloro-N-(((1R,9aS)-octahydro-1H-quinolizin-1-yl) ethyl)
quinolin-4-a ine (+)-A 1.
Both the racemate and its purified enantiomers showed potent antimalarial in vitro activity
against both CQ-S (D10) and CQ-R (W-2) strains of P. falciparum, and a good therapeutic index [25].
In the present work, we extended the previous observations by completing in vivo efficacy studies
of racemic AM1 and its purified enantiomers in two rodent malaria models (P. berghei and P. yoelii) with
different susceptibilities to CQ, and activity studies against P. vivax clinical isolates. We also evaluated
the ADME-Tox profiles in vivo and in vitro.
2. Results
2.1. In itro nti alarial ctivity against P. falciparu and P. vivax
ace ic 1 and its purified enantio ers (Figure 1) sho ed an anti alarial activity in vitro in
the lo nano olar range (I 50 = 16–53 nM) when tested against both CQ-S (D10) and CQ-R strains
of P. falciparum (FCR1 and FCR3), including a ultidrug-resistant parasite T 91 235 (isolated in
Thailand) (Table 1). ll the co pounds had very lo toxicity and an excellent selectivity index
(SI > 1000) against human endothelial cells and fibroblasts, and ouse cell lines, as previously
reported [25]. Furthermore, (±)-AM1 showed remarkable antimalarial activity against 10 different
field isolates of P. vivax with potency about 3 times higher than that of CQ (Table 1, right column).
a le 1. I itro a ti alarial acti ities f t e 1 race ate a its e a ti ers . falcipar
l r t r str i s . vivax field isolates.
Compounds
P. falciparum IC50 (nM) a P. vivax IC50 (nM) b
D10 c (CQ-S) W-2 c (CQ-R) TM91C235 FCR1 FCR3 Field Isolates
(±)-AM1 16.15 35.44 - - - 29.72
(−)-AM1 23.98 53.67 16.74 32.87 23.28 -
(+)-AM1 17.49 35.77 - - - -
CQ 23.72 437.62 199.46 181.93 112.56 86.66
a The assay was evaluated after 72 h incubation, using the parasite lactate dehydrogenase (pLDH) method, mean of
3 different experiments. b IC50 results f o 10 field isolat from the Thai–Burmese Border. c Data already p blished
in [25].
i l t t ( )- 1 iti ti it i ,
a non-significant trend toward antagonism (Figure 2A,B). The results are similar to those obtained
wi h CQ (Figure 2C,D).
Molecules 2017, 22, 2102 4 of 15
Molecules 2017, 22, 2102 4 of 15 
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antagonistic or synergistic effects, respectively. 
2.2. In Vivo Oral Efficacy Studies 
Racemic AM1, (−)-AM1, and (+)-AM1 were tested for oral in vivo efficacy in the four-day mouse 
infection model against P. berghei ANKA [26] and P. yoelii. The data, expressed as ED50 and ED90 
values, are reported in Table 2. 
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a CD1 mice were inoculated i.p. with 4 × 106 infected erythrocytes/mouse. Four drug doses of compounds, 
dissolved in standard suspending formula (SSV), were administered orally, once a day for four days, 
starting two hours post-infection. Percent parasitaemia was evaluated by microscopic examination of 
Giemsa-stained smears taken on day 4. ED50 and ED90 values were calculated by GraphPad Prism6. 
All animal work at The London School of Hygiene and Tropical Medicine (LSHTM) was conducted 
under licence (PPL70/8427) according to UK Home Office regulations: The Animals (Scientific 
Procedures) Act of 1986. 
All compounds showed very good oral efficacy, similar to that of CQ. The ED50 did not differ 
significantly between the two enantiomers, whereas the ED90 of (+)-AM1 was lower than that of 
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DHA fractional IC50 values were calculate i i i t I 50 of HA combined with (−)-AM1 or
CQ, respectively, by the IC50 of DHA alone, an pl tte t e rizontal axis. The corresponding
fractional (−)-AM1 or CQ IC50 values ere calculated by dividing each fixed concentration by the IC50
of the (−)-AM1 or CQ alone, and plotted on the vertical axis. An isobologram close to the diagonal
indicates an additive effect. Curves significantly (>2) above or below the diagonal indicate antagonistic
or synergistic effects, respectively.
2.2. In Vivo Oral Efficacy Studies
Racemic AM1, (−)-AM1, and (+)-AM1 were tested for oral in vivo efficacy in the four-day mouse
infection model against P. berghei ANKA [26] and P. yoelii. The data, expressed as ED50 and ED90
values, are reported in Table 2.
Table 2. Therapeutic efficacy of (±)-AM1, (−)-AM1, (+)-AM1, and chloroquine against P. berghei ANKA
and P. yoelii infection in mice using the Standard four-day Test.
Compounds
P. berghei a P. yoelii a
ED50 (95% CI)
(mg/kg)
ED90 (95% CI)
(mg/kg)
ED50 (95% CI)
(mg/kg)
ED90 (95% CI)
(mg/kg)
(±)-AM1 2.77 (1.26–4. 9) 12.58 (7.69–17.46
(−)-AM1 2.05 (1.31–2.79) 8.65 (7.06–10.23) 1.55 (1.25–1.92) 4.95 ( .08–7.94)
(+)-AM1 1.60 (1.08–2.11) 2.03 (1.46–2.60)
Chloroquine 1.12 (0.98–1.26) 2.93 (2.64–3.22) <3 58.5 (5.38–6.42)
a CD1 mice ere inoculated i.p. with 4 × 106 infected erythrocytes/mouse. Four drug doses of compounds,
dissolved in standard suspending formula (SSV), were administered orally, once a day for four days, starting
two hours post-infection. Percent parasitaemia was evaluated by microscopic examination of Giemsa-stained
smears taken on day 4. ED50 and ED90 values were calculated by GraphPad Prism6. All animal work at The London
School of Hygiene and Tropical Medicine (LSHTM) was conduct d under licence (PPL70/8427) accord ng to
UK Home Office regulations: The Animals (Scientific Procedures) Act of 1986.
All compounds showed very goo ral efficac , si ilar to that of CQ. The ED50 id not differ
significantly between the two enantio ers, hereas the E 90 of (+)-AM1 was lower than that of
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(−)-AM1 and the racemate, and identical to that of CQ. In the P. yoelii model, which is considered
relatively CQ-resistant, the (−)-AM1 enantiomer maintained its antimalarial activity, while CQ had
lower efficacy, as expected. The maximum tolerated dose, MTD, in CD1 mice treated with (−)-AM1
was greater than 100 mg/kg, i.p. No toxic clinical signs or mortality were noted up to this dose.
Similar results were obtained using the compounds as free bases or as water soluble salts, confirming
a therapeutic index greater than that observed for CQ (MTD 50 mg/kg i.p.).
2.3. In Vivo Transmission-Blocking and Prophylactic Effects
Having demonstrated a high in vivo oral efficacy against asexual blood-stages in the four-day
test, we investigated the activity of the (−)-AM1 enantiomer on the transmission stages of the rodent
malaria parasite P. berghei ANKA and Anopheles stephensi mosquitoes. BALB/c mice, four days after
infection with P. berghei, were treated orally with 50 mg/kg of (−)-AM1 and anesthetized and submitted
to the bites of A. stephensi mosquitoes one hour later. After 10 days, a high proportion (86.4%) of
mosquitoes infected with gametocytes from (−)-AM1-treated mice hosted oocysts on their midgut
(CI95 81.4–103.6%). This was not different from control mosquito positivity (90%, CI95 80.6–99.4%).
Similarly, there was not a significant difference in infection intensity, i.e., the number of oocysts
per midgut, between mosquitoes infected with gametocytes from (−)-AM1-treated mice or controls:
an average of 54.11 (CI95 39.77–68.45) and 39.17 (CI95 18.44–59.89) oocysts were found, respectively
(Student’s t-test p = 0.24).
When tested for prophylactic activity (see M&M for details), no significant differences in
parasitaemia in (−)-AM1 treated mice compared to control mice were seen during the entire evaluation
period (days 5–9 post-infection). It can be concluded that in the present model, (−)-AM1 does not
show transmission-blocking or prophylactic activity.
2.4. Metabolic Stability and Biotransformation Studies in Rat, Mouse, and Human Microsomes
Preliminary experiments were then conducted to explore the ADME properties of these
compounds. When evaluated in hepatic microsomes (Figure 3), racemic AM1 and its enantiomers
showed high metabolic stability (greater than 50% remaining at 30 min) in both rat and human
species, comparable to that of CQ. On the contrary, in the mouse microsomes, all the compounds were
moderately unstable (from 16 to 47% remaining at 30 min), with racemic AM1 and (+)-AM1 less stable
than (−)-AM1. Standard reference compounds propranolol and 7-ethoxycoumarin were metabolized
as expected [27].
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Figure 3. Metabolic stability studies in mouse, rat, and human microso es. Hepatic metabolic stability
of the AM1 racemate and its enantio ers was determined in the micr somes of mouse, rat, and human
species after 30 min incubation. 7-EC and propranolol were used as reference compounds. Results
are expressed as Mean ± S.D., n = 2. Metabolic stability range values: >50: High; 10–50: Medium;
<10: Low.
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Biotransformation studies were performed only on (−)-AM1 in rat, mouse, and human hepatic
microsomes in order to identify major metabolites and highlight possible differences among species.
A representative chromatogram in the mouse and the MS spectra are shown in Figure S1
(Supplementary Materials), while the proposed structures of metabolites in all the species, together
with the retention times, are shown in Table 3. In the same table, the metabolites found in mouse
plasma after 50 mg/kg oral treatment are included. The retention times and [M + H]+ of the metabolites
are the same for all three species.
Table 3. In vivo and in vitro main metabolites of (−)-AM1 and their proposed structures.
MH+ (rt, min) Proposed Structure
Metabolic Products Detected In Vitro and In Vivo
In Vitro Microsomes
(−)-AM1 1 µM
In Vivo Plasma Levels after
50 mg/kg Oral Gavage
Human Rat Mouse Mouse
At 30 Min At 120 Min
330 (6.1)
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2.5. P450 and hERG Interaction
The potential for inhibition of the major human P450 isoenzymes was also investigated. Racemic
AM1 and the two enantiomers all showed a similar profile. At 3 µM, all compounds caused strong
inhibition (>60%) of the CYP2D6 activity, with only a slight inhibition of the remaining four isoform
activities (Table 4). It is worth mentioning that CYP2D6 is the only P450 isoenzyme which is also
inhibited by CQ (Table 4) and confirmed in drug–drug interaction studies in humans [28].
The 4-aminoquinoline class of molecules is associated with potential cardiovascular side effects.
Preliminary experiments of hERG binding indicated that (±)-AM1 and (−)-AM1 inhibit hERG with
a Ki in the range of 0.5–0.8 µM, whilst chloroquine in the same experiments had a Ki of 2.2 µM.
Electrophysiological functional assays will be required to further exclude this liability.
Table 4. Comparative P450 inhibition potential of racemic AM1, its enantiomers, and chloroquine.
Compounds
P450 Interaction—Gentest Kit
CYP1A2 CYP2C9 CYP2C19 CYP2D6 CYP3A4
CEC a MFC CEC AMMC BFC
Mean % Inhibition at 3 µM b
(±)-AM1 <5 5.7 ± 0.2 6.0 ± 1.6 61.4 ± 2.0 11.6 ± 0.4
(+)-AM1 8.3 ± 0.8 11.1 ± 0.5 9.0 ± 1.1 62.2 ± 1.0 14.3 ± 1.9
(−)-AM1 <5 <5 5.0 ± 1.3 74.4 ± 3.5 8.4 ± 0.8
CQ <5 <5 <5 20.4 ± 1.1 6.8 ± 1.7
a Substrates: CEC: 3-Cyano-7-ethoxycoumarin; MFC: 7-Methoxy-4-trifluoromethylcoumarin; AMMC:
3-[2(N,Ndiethyl-N-methylamino)ethyl]-7-methoxy-4-methylcoumarin; BFC: 7-Benzyloxy-4-(trifluoromethyl)-
coumarin. b Results are expressed as Mean ± S.D., n = 2; <5% inhibition is considered no effect.
2.6. Pharmacokinetics
Table 5 reports the kinetic parameters evaluated after oral administration 10 mg/kg of the AM1
racemate and its enantiomers to CD1 mice. No significant differences in maximal plasma concentration
achieved among the racemate or its enantiomers were observed. Cmax was about 0.10 µM for all
compounds and the AUC 20 min·µM after oral administration of 10 mg/kg.
The (−)-AM1 enantiomer was also orally injected to the mice at three increasing doses (10, 25,
and 50 mg/kg) and dose proportionality was displayed, together with a parallel kinetic of elimination
of the three treatments, independently from the given dose (Figure S5).
Table 5. Pharmacokinetic parameters of the AM1 racemate and its enantiomers.
Parameters a
(±)-AM1 (+)-AM1 (−)-AM1
10 mg/kg
Cmax (µM) 0.0996 0.108 0.084
Cmax (ng/mL) 32.78 35.48 27.60
Tmax (min) 30 120 15
MRT last (min) 196 162 200
AUC last (min·µM) 19.5 22.9 18.8
AUC last (min·ng/mL) 6421 7551 6179
a Pharmacokinetic parameters were determined by the non-compartmental analysis WinNonlin 5.1, linear
trapezoidal, uniform weight. The following parameters were calculated: Cmax (maximum plasma concentration),
Tmax (time take to reach Cmax), MRT (mean residence time), AUC (area under the curve). In vivo PK experiments
were performed with male CD-1 mice orally-treated by a single dose (10 mg/kg) of the AM1 racemate and single
enantiomers, each dissolved in SSV. Blood samples were collected at eight selected time-points (15, 30, and 60 min;
2, 4, 6, 8, and 24 h) under ethyl ether anaesthesia, and plasma samples analyzed by LC/MS/MS.
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3. Discussion
Historically, the 4-aminoquinolines are a very successful chemical class of antimalarials,
which includes chloroquine and amodiaquine, still clinically used against P. vivax infection or
in combination therapy against P. falciparum. In addition to their direct antiparasitic activity,
the advantages of most of the 4-aminoquinolines are stability, high bioavailability, favorable PK/PD
properties after oral administration, and low cost. For these reasons, although the emergence and
spread of resistant P. falciparum strains significantly affected the use of chloroquine as monotherapy,
research on a new generation of 4-aminoquinolines effective against multiresistant P. falciparum strains
never stopped and novel compounds are presently in development.
This is the case for ferroquine and for AQ-13, in which a ferrocenyl moiety or a short
diethylaminopropyl group replaced the side chain of chloroquine, respectively [16,29,30]. Both
compounds successfully completed phase I studies [19,20] in human volunteers and in asymptomatic
patients, and are presently under phase II efficacy studies, either alone or in combination (https:
//clinicaltrials.gov/ct2/show/NCT01614964, https://clinicaltrials.gov/ct2/show/NCT02497612).
In both cases, the ability to overcome CQ resistance has been attributed to the modification of
the lateral side chain of the 4-aminoquinoline ring, with the introduction of the ferrocene moiety as
in ferroquine, or by reducing its length as in AQ13. Similarly, the compound AM1, described in this
paper, was obtained by the introduction of a bulky, basic, and lipophilic quinolizidine ring (N-lupinyl)
in the lateral chain of a 7-chloro-4-aminoquinoline [22], leading to a compound more lipophilic than
CQ (AM1 LogD7.4 = 2.26 vs. CQ LogD7.4 = 0.90) [23]. Differently from the semisynthetic product
which used (−)-lupinine as starting material, the total synthesis of AM1 lead to the formation of a
racemate, which was then tested for antimalarial activity and toxicity in vitro together with the isolated
enantiomers. The total synthesis of (±)-AM1 is cheap and straightforward, and can be accomplished
in four steps using commercially available material [25].
The AM1 enantiomers displayed in vitro activity similar to the racemate, which supports further
studies on the in vivo efficacy of these compounds and on the analysis of their pharmacokinetic and
ADME/tox properties.
Here, we report the activity of (±)-AM1 and its enantiomers in the low nanomolar range
documented against laboratory chloroquine-resistant P. falciparum strains, as well as the multidrug
resistant strain TM91C235 strain from Thailand. In combination studies with DHA, (−)-AM1 displayed
an additive effect similar to that obtained with CQ and DHA in combination. Therefore, the profile of
the compound appears good in terms of possible administration against CQ-resistant strains and in
combination with artemisinin.
Moreover, (±)-AM1 displayed an inhibitory activity three-fold higher than chloroquine against
ten field isolates of P. vivax, an infection that accounts for approximately 4% of malaria cases worldwide,
41% of which occur outside Africa [1]. The WHO’s recommendation for the treatment of P. vivax
infections is chloroquine, in non-chloroquine resistant areas, or ACT. However, in areas where
chloroquine-resistant P. vivax infections have been identified, ACT should be the preferred choice.
All ACTs, except the artesunate + sulfadoxine-pyrimethamine (AS + SP) combination, are demonstrated
to be effective against the blood-stage infections of P. vivax. The in vitro and in vivo data reported for
(±)-AM1 support its possible development against P. vivax, as well.
The AM1 racemate and its enantiomers were orally active at suitable doses in the classical in vivo
four-day test in mice as schizonticidal agents, with no significant differences in potency among
(±)-AM1 and its enantiomers. They were inactive against the parasite transmission stages in the
P. berghei/A. stephensi model. These results are consistent with previous data on this class of drugs [31].
However, for other 4-aminoquinolines recently synthesized (TDR58445 and TDR58446), a reduction
of activity in both early and late gametocytes stages has been described [32], although at a relatively
higher concentration (1 µM), compared to the activity on asexual stages.
In terms of in vitro metabolic stability and interference with the P450 enzymes, racemic AM1 and
its enantiomers did not differ significantly from chloroquine, used as reference drug. Similarly,
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the binding assay to hERG indicated that these molecules may share a potential liability for
cardiovascular side effects with the quinoline antimalarials, including chloroquine and piperaquine,
currently recommended by WHO for malaria therapy [33]. In the case of future developments,
more stringent methods of analysis will be necessary.
PK studies in animals were performed by oral gavage according to the target product profile for
an antimalarial drug. The need for a complex formulation (SSV) was dictated by the poor solubility of
the free bases, which could also have an impact on total drug disposition.
This information is of relevance in respect to the in vivo efficacy data. In fact, all efficacy
experiments have been performed with the compounds prepared as free bases, suggesting that the
in vivo data obtained so far could underestimate the potential of the test compound as antimalarial.
The introduction of a bulky bicyclic tertiary amine in place of the diethylaminoalkyl chain
typical of CQ and AQ13 changed the metabolic profile, thus N-dealkylation is not the preferred
metabolic pathway. This aspect could be important because it has been demonstrated that the major
CQ metabolites, desethylchloroquine (DEC) and, overall, bisdesethylchloroquine (bisDEC), are less
active than the parent compound on CQ-resistant strains of P. falciparum [34]. Similarly to CQ, in vivo
studies on AQ13 metabolites showed that its N-deethylation led to specific changes in lipophilicity
and increased the cross-resistance of this compound even more than that of CQ [35]. The main AM1
metabolite seems to be an N-oxide on the amino methylene bridge. In terms of metabolic stability,
this difference does not increase the half-life of AM1 compared to CQ, but could change the in vitro
antimalarial profile. It remains to be elucidated how the in vivo antimalarial activity of AM1 is
influenced by these metabolites.
In conclusion, we have demonstrated that the 4-aminoquinoline compounds remain of high
interest as antimalarial agents, and AM1 in particular displays a very attractive profile in terms of
in vitro and in vivo activity.
4. Materials and Methods
4.1. Compounds
Racemic AM1 and its enantiomers (Figure 1) were synthesized as previously described [25,36].
Chloroquine and all the other reagents, unless indicated, were purchased from Sigma (Sigma Italia,
Milan, Italy).
4.2. Cultures of P. falciparum and In Vitro Chemosensitivity Assays
The strains D10 and 3D7 (CQ-Sensitive), and W-2, FCR1, FCR3 (CQ-Resistant), and TM91C235
(multidrug-resistant) of P. falciparum were cultured in vitro as described by Trager and Jensen
with minor modifications [37]. Briefly, parasites were maintained at 5% hematocrit (human type
A+ red blood cells) in RPMI 1640 (EuroClone, Celbio, Pero, Italy) medium with the addition of 10%
heat-inactivated human serum, 20 mM Hepes, and 2 mM glutamine (EuroClone). The cultures were
maintained at 37 ◦C in a standard gas mixture consisting of 1–3% O2, 5% CO2, and 92–94% N2.
Compounds were dissolved in either water or DMSO and then diluted with medium to achieve
the required concentrations (final DMSO concentration <1%, which is non-toxic to the parasite).
Asynchronous cultures of P. falciparum with parasitaemia of 1–1.5% and 1% final hematocrit were
aliquoted into 96-well flat-bottom microplates (COSTAR) with serial dilutions of test compounds,
and incubated for 72 h at 37 ◦C. Parasite growth was determined spectrophotometrically (OD650) by
measuring the activity of the parasite lactate dehydrogenase (pLDH) according to a modified version of
the method of Makler, in control and drug-treated cultures [38]. The antimalarial activity is expressed
as 50% inhibitory concentrations (IC50); each IC50 value is the mean and standard deviation of at least
three separate experiments performed in duplicate [22].
The antimalarial activity of (−)-AM1 was assayed in combination with dihydroartemisinin
(DHA) against W-2 (CQ-R) or D10 (CQ-S) strains of P. falciparum by potentiation tests as previously
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described [39]. CQ was used as a control. Isobolograms were constructed by plotting a pair of fractional
IC50 values for each combination of (−)-AM1 or CQ with DHA [40].
An isobologram close to the diagonal indicates an additive effect. Curves significantly (>2) above
or below the diagonal indicate antagonistic or synergistic effects, respectively.
4.3. In Vitro Assays against P. vivax Field Isolates
Ten P. vivax isolates were collected from June to July 2010 from malaria patients attending the
Shoklo Malaria Research Unit (SMRU) clinics, Mae Sot region of the Tak Province in north-western
Thailand under the ethical guidelines in the approved protocol OXTREC 027-05 (Centre for Clinical
Vaccinology and Tropical Medicine, University of Oxford, Oxford, UK). These samples were collected
from patients with no prior antimalarial therapy and with microscopically confirmed P. vivax.
After written consent, blood samples were collected by venepuncture in 5 mL volume lithium
heparinized tubes, which were then transported to the laboratory at SMRU within 5 h of collection.
The ten isolates were chosen for testing because the majority (>80%) of the parasites were at the mid
trophozoite stage (around 20 h post invasion) and no schizonts were detected. After platelet and
leukocyte removal [41], the susceptibility of these P. vivax isolates to AM1, chloroquine diphosphate
(MW 515.9, Sigma-Aldrich®, Milan, Italy), and artesunate (Base MW282.3, Holly Pharmaceuticals
Co Ltd., Tustin, CA, USA) was assessed as previously described [42,43].
4.4. In Vivo Efficacy Tests and Transmission-Blocking/Prophylactic Activities
In vivo antimalarial efficacy tests were performed using P. berghei (CQ sensitive, CQ-S) ANKA
and P. yoelii (CQ resistant, CQ-R) rodent species in the standard four-day suppressive Peters’ test [26].
Groups of five CD1 mice were inoculated i.v. with 4 × 106 infected erythrocytes/mice. The compound,
dissolved in standard suspending formula (SSV) (0.5% sodium carboxymethylcellulose, 0.5% benzyl
alcohol, 0.4% Tween 80, 0.9% NaCl), was administered orally, once a day for a period of four days,
starting two hours post-infection. Four drug doses were used, ranging from 1 to 30 mg/kg to
determine ED50 and ED90 values. Parasitaemia was determined by microscopic examination of
Giemsa-stained blood films taken on day four, processed using MICROSOFT® EXCEL spreadsheets
(Microsoft Corp., Redmond, WA, USA), and expressed as percentages of inhibition from the arithmetic
mean parasitaemias of each group in relation to the untreated group. ED50 and ED90 values were
calculated by GraphPad Prism 6 (GraphPad Software Inc, La Jolla, CA, USA).
(−)-AM1 was also tested in transmission-blocking and prophylactic studies using the P. berghei/
A. stephensi model as described, with a few modifications [44].
For the transmission-blocking test, four BALB/c female mice (18–20 g) were infected i.p. with
107 P. berghei-infected red blood cells. Four days later, once confirmed for gametocyte carriage, two mice
were treated with 50 mg/kg (−)-AM1, through the oral administration of 500 µL of a methylcellulose
suspension, obtained by dissolving a 20 mg/mL ethanol stock solution in 0.5% methylcellulose
to a final 9% ethanol concentration. Two mice received the vehicle only as controls. One hour
after the treatment, mice were anesthetized and exposed to the bites of 100 sugar-starved female
mosquitoes, at 20 ◦C. Ten days after the blood meal, samples of mosquito midguts from each treatment
(n = 40) were dissected and P. berghei oocysts were manually counted using light microscopy at
400× magnification. Oocyst numbers were log-transformed and the geometric means were compared
using the Student’s t-test.
For the prophylactic test, the experimental drugs were administered at 50 mg/kg per os for
4 consecutive days; 90 min after the last administration, mice were infected by 6–10 infective mosquito
bites. Thick and thin Giemsa-stained smears were prepared and examined on days 5–10 post-infection
to assess parasite density per µL of blood.
Rearing and handling of experimental animals was in full compliance with the Italian
Legislative Decree on the “protection of animals used for experimental and other scientific purposes”
(D. Lgs. 26 of 03/04/2014) and in full adherence with the European Directive 2010/63/UE.
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4.5. LC–MS/MS Analytical Methods
Samples from the metabolic stability and metabolism studies were analyzed under the following
conditions: UPLC interfaced with a Premiere XE triple Quadrupole Waters for stability studies,
and Bruker Daltonics Ion Trap HCT Ultra for metabolic studies. A gradient from 2% to 100% (Water,
MeOH, 5 mM Ammonium Acetate) over 2 min (stability) or 12 min (metabolism) in a C18 BEH
(dimensions 1 by 50 mm for stability and 2.1 by 100 mm for metabolism, 1.7 µm column, 45 ◦C
temperature, flow rate 0.5 mL/min) was used. For stability studies, the detection was performed in
MRM (ESI positive, Q1/Q3 330.16/152.00, Cone Voltage 45 V; Extractor 5 V; Capillary 3.4 kV), while for
metabolism studies, analysis was performed in Auto MS/MS mode (ESI positive; Capillary 109 V;
Dry Temp 350 ◦C; Nebulizer 30 psi; Dry gas 10 L/min; HV capillary 500 V; Mass Accu time 500 µs;
Mass range MS scan 100–600 amu, MS/MS 50–450 amu).
Samples from the pharmacokinetic studies were analyzed under the following conditions:
UPLC interfaced with a Premiere XE triple Quadrupole, Waters. A gradient from 2 to 100% (Water,
MeOH, 5 mM Ammonium Acetate) over 1.3 min was used in Acquity HSS T3 (dimensions 2.1 by
50 mm, 1.8 µm column, 40 ◦C temperature, flow rate 0.5 mL/min). Detection was performed in MRM
(ESI positive, Q1/Q3 330.16/152.00, Cone Voltage 45 V; Extractor 5 V; Capillary 3.4 kV). The limit
of detection was 1 ng/mL. Pharmacokinetic parameters were determined by Non-Compartmental
Analysis, using the linear trapezoidal rule and uniform weight.
4.6. In Vitro Microsome Stability and Metabolism Studies
For stability and metabolism studies, test compounds were dissolved in DMSO, diluted at the
final concentration of 1 µM, and pre-incubated in duplicate for 10 min at 37 ◦C in potassium phosphate
buffer, pH 7.4, 3 mM MgCl2, with rat, mouse, and human hepatic microsomes (Xenotech Europe,
Pfungstadt, Germany) at the final concentration of 0.5 mg/mL. The reaction was then started by
adding the cofactor mixture of NADP, Glc6P, and G6P-DH, in the presence of UDPGA 1 mM in human
microsomes to promote glucuronide formation. Acetonitrile (with verapamil as internal standard)
was added to the samples at the times time 0 and 30 min to stop the reaction. Samples were then
centrifuged and the supernatants analysed and quantified by LC-MS/MS. Reference compounds of
known metabolic stability, 7-ethoxycoumarin (7-EC) and propranolol, were used as controls.
The percentage of the area of test compounds remaining after 30 min incubation was calculated
in respect to the area of compounds at time = 0 min. A compound showing a % remaining greater than
95% at 30 min was considered stable. In biotransformation studies after, the full scan acquisition data
were processed by MetaboLynx software (Waters Corp., Milford, MA, USA) comparing the signals
at times 0 and 30 min. Samples were re-analyzed by acquiring the daughter scan of the potential
metabolites found during the full scan acquisition.
4.7. Pharmacokinetics
Pharmacokinetic data were collected in mice by testing the racemate and the enantiomers at the
same single dose, and vehicle-utilized for in vivo studies (see composition in paragraph 4.4). Briefly,
male CD-1 mice (Charles River Laboratories) weighing 18–22 g received single dose (10 mg/kg)
oral administrations of the AM1 racemate and single enantiomers, each dissolved in SSV. For each
experiment, twenty-four mice/dose and three mice/time-point were used. Blood samples were
collected at eight selected time-points (15, 30 and 60 min; 2, 4, 6, 8 and 24 h) under ethyl ether
anaesthesia. The heparinized tubes containing blood samples were immediately placed on ice and
centrifuged, and the supernatant collected and frozen at −80 ◦C prior to analysis. Pharmacokinetic
plasma samples (spiked with internal standard) were filtered (Sirocco filter plate, Waters) under
vacuum, and 5 µL analysed by LC-MS/MS.
Molecules 2017, 22, 2102 12 of 15
4.8. P450 Assay
Potential inhibition of the five most important human P450 isoforms (CYP1A2, CYP2C9, CYP2C19,
CYP2D6, and CYP3A4) was measured using BD Gentest assays using specific substrates that become
fluorescent upon CYP metabolism [45]. Compounds, dissolved in DMSO, were tested in duplicate
(n = 2) at 3 µM in a 96-well plate, as described [46]. Specific selective isoform inhibitors were added in
each experiment as controls. The data were expressed as percentage inhibition in respect to the control
without inhibition (<5% inhibition was considered no effect), and for standards, the IC50 (concentration
causing 50% inhibition) was then determined by using Grafit v. 5.0.1 (Erithacus Software Ltd., Horley,
Surrey, UK).
4.9. hERG Binding Assay
[3H]-astemizole (PerkinElmer ITALIA Spa, Milan, Italy) radioligand binding assays were
performed in HEK293 cells membranes stably transfected with the hERG (U04270); non-specific
binding was evaluated in the presence of an excess of 10 µM cold astemizole. Experiments were
performed at 22 ◦C for 60 min in triplicate and compounds tested in a range from 0.03 µM to
30 µM. Two separate experiments were performed and data analyzed with non-linear fitting using a
four-parameter logistic [47].
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